AR127700A1 - Prueba de disolución - Google Patents

Prueba de disolución

Info

Publication number
AR127700A1
AR127700A1 ARP220103162A ARP220103162A AR127700A1 AR 127700 A1 AR127700 A1 AR 127700A1 AR P220103162 A ARP220103162 A AR P220103162A AR P220103162 A ARP220103162 A AR P220103162A AR 127700 A1 AR127700 A1 AR 127700A1
Authority
AR
Argentina
Prior art keywords
samples
evaluation
relates
present
dissolution test
Prior art date
Application number
ARP220103162A
Other languages
English (en)
Inventor
Johannes Jan Moes
Inge Pirlet
Maesschalck Roy Johan E De
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2021/072453 external-priority patent/WO2022109555A1/en
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of AR127700A1 publication Critical patent/AR127700A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)

Abstract

La presente invención se refiere a la evaluación de muestras que comprenden rilpivirina o una sal farmacéuticamente aceptable de esta en forma de micro- o nanopartículas, tales como suspensiones, y a la medición de la disolución de la rilpivirina o una sal farmacéuticamente aceptable de esta en un medio acuoso. La presente invención también se refiere a la evaluación del control de calidad de dichas muestras y a la entrega de lotes que comprenden dichas muestras para uso farmacéutico. La presente invención también se refiere a un medio para su uso en la evaluación de la disolución.
ARP220103162A 2021-11-17 2022-11-16 Prueba de disolución AR127700A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2021/072453 WO2022109555A1 (en) 2020-11-17 2021-11-17 Treatment or prevention of hiv infection
US202263342834P 2022-05-17 2022-05-17
EP22173914 2022-05-17

Publications (1)

Publication Number Publication Date
AR127700A1 true AR127700A1 (es) 2024-02-21

Family

ID=84421043

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220103162A AR127700A1 (es) 2021-11-17 2022-11-16 Prueba de disolución

Country Status (7)

Country Link
KR (1) KR20240095514A (es)
AR (1) AR127700A1 (es)
AU (1) AU2022394742A1 (es)
CA (1) CA3234763A1 (es)
IL (1) IL312784A (es)
TW (1) TW202333725A (es)
WO (1) WO2023088964A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
MX2009000158A (es) 2006-06-23 2009-01-23 Tibotec Pharm Ltd Suspensiones acuosas de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil ]-amino]-2-pirimidinil]-amino]-benzonitrilo.

Also Published As

Publication number Publication date
TW202333725A (zh) 2023-09-01
WO2023088964A1 (en) 2023-05-25
CA3234763A1 (en) 2023-05-25
KR20240095514A (ko) 2024-06-25
IL312784A (en) 2024-07-01
AU2022394742A1 (en) 2024-07-04

Similar Documents

Publication Publication Date Title
Firdessa et al. Identification of multiple cellular uptake pathways of polystyrene nanoparticles and factors affecting the uptake: Relevance for drug delivery systems
Zhou et al. Elucidating the endocytosis, intracellular trafficking, and exocytosis of carbon dots in neural cells
Moreau et al. Autophagosome precursor maturation requires homotypic fusion
Jiang et al. Functional graphene oxide as cancer-targeted drug delivery system to selectively induce oesophageal cancer cell apoptosis
NI201600138A (es) Nanopartículas terapéuticas que comprenden un agente terapéutico, y metodos para su elaboración y uso
PH12018501400A1 (en) Wash-durable, fluid absorbent substrate with antimicrobial properties and/or improved washability, and hygiene product such as reusable sanitary napkin
BR112016009071A8 (pt) Composição cosmética em forma de nanofibras, método de produção de composição e uso
CR10975A (es) Formulaciones para el tratamiento del cancer
BR112017020689A2 (pt) imunoconjugados em nanopartículas
Fede et al. The toxicity outcome of silica nanoparticles (Ludox®) is influenced by testing techniques and treatment modalities
Jensen et al. Lipogels: surface-adherent composite hydrogels assembled from poly (vinyl alcohol) and liposomes
WO2016040891A3 (en) In vitro compositions comprising human sample and amyloid targeting agent
BR112018003331A2 (pt) sondas para imagear proteína huntingtina
BR112017004136A2 (pt) sondas para imageamento de proteína de huntingtina
Weir et al. Host cell virus entry mediated by Australian bat lyssavirus G envelope glycoprotein occurs through a clathrin-mediated endocytic pathway that requires actin and Rab5
AR127700A1 (es) Prueba de disolución
BR112016023740A2 (pt) compostos heteroaromáticos e seu uso como ligantes de dopamina d1
ES2586116T3 (es) Procedimiento y composición para el tratamiento, la prevención y el diagnóstico de cáncer que contiene células madre de cáncer o derivados de las mismas
PH12019500020A1 (en) In vitro release testing method and evaluation method of polymer micelle preparation containing poorly water-soluble drug
ITUB20160543A1 (it) Composizione oftalmica stabilizzante e reintegrante del film lacrimale per uso nella prevenzione delle infezioni virali
IT201700034725A1 (it) Aggregati vescicolari tridimensionali di fosfolipidi dispersi in miscele alcoliche a basso o nullo contenuto d’acqua, loro preparazione e loro uso in formulazioni per applicazione topica
BR112019027348A2 (pt) nanopartículas de albumina para tratamento de câncer e doenças oculares
CL2015000538A1 (es) Uso de molécula de ácido nucleico interferente corta (siarn) para tratar trastorno ocular caracterizado por presión intraocular elevada; dispensador de la composición que comprende sirna; y kit que comprende dispensador e instrucciones.
Zhao et al. Mitochondrial toxicity effect of radix aconiti lateralis praeparata on h9c2 cardiomyocytes
BR112015004346A2 (pt) célula de fluxo de permeabilidade e sistema de condutância hidráulica